Success Metrics

Completion Rate
0%(0/2)
Active Trials
2(29%)
Terminated
2(29%)

Phase Distribution

Ph phase_1
1
14%
Ph phase_2
6
86%

Phase Distribution

1

Early Stage

6

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
6(85.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

2

trials recruiting

Total Trials

7

all time

Status Distribution
Active(5)
Terminated(2)

Detailed Status

Not yet recruiting3
Terminated2
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
7
Active
2
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (14.3%)
Phase 26 (85.7%)

Trials by Status

not_yet_recruiting343%
terminated229%
recruiting229%

Recent Activity

2 active trials
Showing 5 of 7
not_yet_recruitingphase_2

PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy

NCT07463248
not_yet_recruitingphase_2

Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer

NCT07403877
recruitingphase_1

PULSAR Combined With Immunotherapy and Chemotherapy

NCT07291947
terminatedphase_2

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

NCT05846646
not_yet_recruitingphase_2

Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Radiotherapy

NCT07005882
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07463248Phase 2

PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy

Not Yet Recruiting
NCT07403877Phase 2

Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer

Not Yet Recruiting
NCT07291947Phase 1

PULSAR Combined With Immunotherapy and Chemotherapy

Recruiting
NCT05846646Phase 2

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

Terminated
NCT07005882Phase 2

Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Radiotherapy

Not Yet Recruiting
NCT05846659Phase 2

Study of PULSAR-ICI +/- IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies

Terminated
NCT06359275Phase 2

PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients

Recruiting

All 7 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
7